Volume 23, Issue 1-2 293138 pp. 89-96
Article
Open Access

Cancer Diagnosis, Risk Assessment and Prediction of Therapeutic Response by Means of DNA Methylation Markers

Heidi Fiegl

Corresponding Author

Heidi Fiegl

Translational Research Laboratory Department of Gynaecological Oncology Institute of Women’s Health UCL London, UK

Biocentre Innsbruck Division of Cell Biology Medical University Innsbruck, Austria

Search for more papers by this author
Karim Elmasry

Karim Elmasry

Translational Research Laboratory Department of Gynaecological Oncology Institute of Women’s Health UCL London, UK

Search for more papers by this author
First published: 06 June 2013
Citations: 10

Abstract

Epigenetic alterations are heritable changes in gene expression without an accompanying change in primary DNA sequence. Two major mechanisms that cause epigenetic changes are post-translational histone modifications and DNA methylation at cytosine bases within a CpG dinucleotide. Epigenetic defects have turned out to be one of the most common molecular alterations in human neoplasia. Promoter hypermethylation is associated with loss of expression of tumour suppressor genes in cancer. The analysis of aberrant DNA methylation is gaining strength in the fields of cancer risk assessment, diagnosis, and therapy monitoring in different cancer types. These issues are discussed in this review.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.